Literature DB >> 14713265

Estrogen receptor corepressors -- a role in human breast cancer?

K M Dobrzycka1, S M Townson, S Jiang, S Oesterreich.   

Abstract

Estrogen receptor alpha (ERalpha) has an established role in promoting breast cancer. Transcriptional activation by ERalpha is a complex and multistep process, and it is influenced by coactivator and corepressor proteins that can either positively or negatively modulate ERalpha-mediated transcriptional activity. Corepressors are proposed to provide a counterbalance to the estrogen-induced transactivation, and represent a potential mechanism employed by the cell to regulate hormonal responses. In this review, we present evidence from tissue culture, animal and clinical studies, supporting the hypothesis that corepressors are crucial regulators of ERalpha-mediated action, and that their loss could promote breast cancer development and resistance to endocrine therapy. We propose that ERalpha corepressors play an important biological role by controlling the magnitude of the estrogen response, mediating antiestrogen inhibition of ERalpha, repressing DNA-bound ERalpha in the absence of the ligand, and conferring active repression of ERalpha-downregulated genes. Different ERalpha corepressors regulate steroid receptor activity through a variety of mechanisms, including formation of multiprotein complexes that are able to affect chromatin remodeling, histone deacetylation, or basal transcription. Other mechanisms include competition with coactivators, interference with DNA binding and ERalpha homodimerization, alteration of ERalpha stability, sequestration of ERalpha in the cytoplasm, and effects on RNA processing. Most ERalpha corepressors can control the receptor's activity through more than one mechanism, and it is possible that the synergy between different pathways cooperates to fully inhibit ERalpha transcriptional activity, and create an integrated response to a variety of different cellular signaling pathways. We will discuss the role of corepressors in tumor suppression and the link they might present between ERalpha regulation and DNA repair. Finally, we will discuss major challenges in the field and speculate on the exciting findings that await us in the next few years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14713265     DOI: 10.1677/erc.0.0100517

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  48 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells.

Authors:  Steven M Townson; Kaiyan Kang; Adrian V Lee; Steffi Oesterreich
Journal:  Biochem Biophys Res Commun       Date:  2006-08-22       Impact factor: 3.575

Review 3.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

4.  Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells.

Authors:  Peng Guo; Xue-Yuan Dong; Ke-Wen Zhao; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

5.  Increased PELP1 expression in rat periodontal ligament tissue in response to estrogens treatment.

Authors:  Jing Wang; Qiang Zhu; Shujun Song; Jun Dong; Lixin Shi; Ran Tao; Yin Ding; Baofa Hong
Journal:  J Mol Histol       Date:  2013-02-24       Impact factor: 2.611

Review 6.  Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.

Authors:  Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

7.  Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2007-09-29       Impact factor: 2.668

8.  SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.

Authors:  Stephanie Hammerich-Hille; Benny A Kaipparettu; Anna Tsimelzon; Chad J Creighton; Shiming Jiang; Jose M Polo; Ari Melnick; Rene Meyer; Steffi Oesterreich
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

9.  Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.

Authors:  Ben Davidson; Tian-Li Wang; Ie-Ming Shih; Aasmund Berner
Journal:  Hum Pathol       Date:  2008-03-04       Impact factor: 3.466

10.  A novel Na+ channel splice form contributes to the regulation of an androgen-dependent social signal.

Authors:  He Liu; Ming-ming Wu; Harold H Zakon
Journal:  J Neurosci       Date:  2008-09-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.